skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Primacy of cardiac chymase over angiotensin converting enzyme as an angiotensin-(1-12) metabolizing enzyme

Journal Article · · Biochemical and Biophysical Research Communications
 [1];  [1];  [2];  [2];  [3];  [4];  [1]
  1. General Surgery, Wake Forest University School of Medicine, Winston-Salem, NC (United States)
  2. Hypertension and Vascular Research Center, Wake Forest University School of Medicine, Winston-Salem, NC (United States)
  3. Department of Cell, Developmental and Integrative Biology, University of Alabama at Birmingham, Birmingham, AL (United States)
  4. Division of Cardiovascular Disease, Department of Medicine, University of Alabama at Birmingham, Birmingham VA Medical Center, Birmingham, AL (United States)

We showed previously that rat angiotensin-(1-12) [Ang-(1-12)] is metabolized by chymase and angiotensin converting enzyme (ACE) to generate Angiotensin II (Ang II). Here, we investigated the affinity of cardiac chymase and ACE enzymes for Ang-(1-12) and Angiotensin I (Ang I) substrates. Native plasma membranes (PMs) isolated from heart and lung tissues of adult spontaneously hypertensive rats (SHR) were incubated with radiolabeled {sup 125}I-Ang-(1-12) or {sup 125}I-Ang I, in the absence or presence of a chymase or ACE inhibitor (chymostatin and lisinopril, respectively). Products were quantitated by HPLC connected to an in-line flow-through gamma detector. The rate of {sup 125}I-Ang II formation from {sup 125}I-Ang-(1-12) by chymase was significantly higher (heart: 7.0 ± 0.6 fmol/min/mg; lung: 33 ± 1.2 fmol/min/mg, P < 0.001) when compared to {sup 125}I-Ang I substrate (heart: 0.8 ± 0.1 fmol/min/mg; lung: 2.1 ± 0.1 fmol/min/mg). Substrate affinity of {sup 125}I-Ang-(1-12) for rat cardiac chymase was also confirmed using excess unlabeled Ang-(1-12) or Ang I (0–250 μM). The rate of {sup 125}I-Ang II formation was significantly lower using unlabeled Ang-(1-12) compared to unlabeled Ang I substrate. Kinetic data showed that rat chymase has a lower K{sub m} (64 ± 6.3 μM vs 142 ± 17 μM), higher V{sub max} (13.2 ± 1.3 μM/min/mg vs 1.9 ± 0.2 μM/min/mg) and more than 15-fold higher catalytic efficiency (ratio of V{sub max}/K{sub m}) for Ang-(1-12) compared to Ang I substrate, respectively. We also investigated ACE mediated hydrolysis of {sup 125}I-Ang-(1-12) and {sup 125}I-Ang I in solubilized membrane fractions of the SHR heart and lung. Interestingly, no significant difference in {sup 125}I-Ang II formation by ACE was detected using either substrate, {sup 125}I-Ang-(1-12) or {sup 125}I-Ang I, both in the heart (1.8 ± 0.2 fmol/min/mg and 1.8 ± 0.3 fmol/min/mg, respectively) and in the lungs (239 ± 25 fmol/min/mg and 248 ± 34 fmol/min/mg, respectively). Compared to chymase, ACE-mediated Ang-(1-12) metabolism in the heart was several fold lower. Overall our findings suggest that Ang-(1-12), not Ang I, is the better substrate for Ang II formation by chymase in adult rats. In addition, this confirms our previous observation that chymase (rather than ACE) is the main hydrolyzing enzyme responsible for Ang II generation from Ang-(1-12) in the adult rat heart.

OSTI ID:
22696576
Journal Information:
Biochemical and Biophysical Research Communications, Vol. 478, Issue 2; Other Information: Copyright (c) 2016 Elsevier Science B.V., Amsterdam, The Netherlands, All rights reserved.; Country of input: International Atomic Energy Agency (IAEA); ISSN 0006-291X
Country of Publication:
United States
Language:
English

Similar Records

GPR30 decreases cardiac chymase/angiotensin II by inhibiting local mast cell number
Journal Article · Fri Mar 27 00:00:00 EDT 2015 · Biochemical and Biophysical Research Communications · OSTI ID:22696576

Angiotensin converting enzyme gene polymorphism in familial hypertrophic cardiomyopathy patients
Journal Article · Thu Sep 01 00:00:00 EDT 1994 · American Journal of Human Genetics · OSTI ID:22696576

Chronic infusion of enalaprilat into hypothalamic paraventricular nucleus attenuates angiotensin II-induced hypertension and cardiac hypertrophy by restoring neurotransmitters and cytokines
Journal Article · Sat Feb 01 00:00:00 EST 2014 · Toxicology and Applied Pharmacology · OSTI ID:22696576